Dr. Andrews has over 8 years of preclinical development experience with antibody, vaccine and antiviral therapeutic candidates. This work has spanned small and large animal model development, cGMP manufacturing and GLP toxicology programs, and their related regulatory filings. Dr. Andrews conducted her postdoctoral studies in the laboratory of David D. Ho at the Aaron Diamond AIDS Research Center, an affiliate of The Rockefeller University.
Some of her lead author publications during this tenure included demonstrating the antiviral protective efficacy of cabotegravir in rhesus macaques in collaboration with ViiV Healthcare and GlaxoSmithKline, and demonstrating the protective efficacy of antibody gene transfer against lethal influenza and Ebola infections in mice. Earlier in her career, Dr. Andrews worked at AlphaVax Human Vaccine in Research Triangle Park, NC. Dr. Andrews received her PhD in Pharmaceutical Sciences from the University of Michigan and her Bachelor of Science in Chemistry from the University of North Carolina.